Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 17,755 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Population Clear all

Conditions: Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Eosinophilia
Interventions: Benralizumab, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Education, Asthma, Obesity
Interventions: Collaborative Management in Pediatrics (CMP) Program; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 2 Years to 12 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Vaccination Refusal, COVID-19 Pandemic
Interventions: Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order; Behavioral
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Herpes Simplex
Interventions: Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more

Conditions: Burns, Burn Scar, Contracture
Interventions: Technology-assisted rehabilitation, Usual care; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Adolescent Behaviors
Interventions: Gradebook Game; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 7 Years to 17 Years
Enrollment: 100 participants
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Degenerative Lumbar Spinal Stenosis, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Disease
Interventions: Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Patient Satisfaction
Interventions: Thank you card; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: Not listed
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Dementia, Alzheimer Disease, Memory Loss
Interventions: Care to Plan, Usual Care; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Down Syndrome
Interventions: Combined exercise intervention, Usual care / Sham intervention; Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Type 2 Diabetes
Interventions: Pharmacist Only, Continuous Glucose Monitor (CGM), Community Health Worker (CHW); Behavioral · Device
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 25 Years to 75 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Glaucoma
Interventions: Pilocarpine, Prednisolone, Ofloxacin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Depression, Trauma, Psychological
Interventions: Not listed
Lead sponsor: Mclean Hospital; Other
Eligibility: 20 Years to 32 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: SUDEP
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Knee, Knee Osteoarthritis, Patellofemoral Osteoarthritis
Interventions: HYMOVIS plus Physical Exercise Program (PEP), Physical Exercise Program (PEP) alone; Device · Other
Lead sponsor: Fidia Pharma USA Inc.; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Tucson, Arizona • Encinitas, California • Los Angeles, California + 5 more

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Dapagliflozin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more

Conditions: Hernia, Abdominal, Pain
Interventions: acetominophen, ibuprofen, oxycodone, Oxycodone; Drug
Lead sponsor: Khashayar Vaziri; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Trust
Interventions: Influencer Instagram account, Research study Instagram account; Behavioral
Lead sponsor: California State Polytechnic University, Pomona; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Pomona, California

Conditions: Alzheimer's Disease and Related Dementia
Interventions: DERA Online Training Program; Behavioral
Lead sponsor: George Mason University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Menopause, Cognitive Change, Brain Disorder, Metabolic
Interventions: PhytoSERM, Placebo; Dietary Supplement · Drug
Lead sponsor: Roberta Brinton; Other
Eligibility: 45 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Tucson, Arizona • New York, New York

Conditions: Vision, Eye Health
Interventions: Carotenoid Group, Control (placebo) group; Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 20 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea; Drug · Other
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more

Conditions: Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 2 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Stockton, California • Tustin, California

Conditions: Fracture Mandible
Interventions: Stryker Hybrid, Erich; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

Evaluating the Collaborative Management in Pediatrics (CMP) Training Program Among Pediatric Resident Doctors and Their Patients With Asthma or Obesity

COVID-19 Messaging for Vaccination

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

A Prospective Trial of Virtual Home Rehabilitation After Burn Injury

Grade Book Game Evaluation Among 6th Grade Students

Effect of RECK in Posterior Spinal Fusion

Increasing Patient Experience Survey Responses

Care to Plan: a Tailored Resource for Family Members of Persons With Dementia

Blood Flow Regulation in Individuals With Down Syndrome - Training Study

A Community Health Worker/Pharmacist Team to Improve Blood Sugars in Diabetes Care Using Continuous Glucose Monitoring

Pilocarpine Use After Kahook Goniotomy

Early Life Stress and Depression: Molecular and Functional Imaging

Risk Factors for Sudden Unexplained Death in Epilepsy

2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

Multimodal Pain Therapy After Hernia Repair

Physical Activity and Social-media Support

Randomized Controlld Trial of Dementia Education Resources for Action

PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition

Eye and Carotenoid Augmentation Research and Evaluation (EyeCARE)

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

A Comparison of Stryker Hybrid Arch Bars